The Impact of Minimal Residual Disease (MRD) Testing on the Decision-Making Process in Non-Small-Cell Lung Cancer (NSCLC)
: In this real-world cohort, MRD testing was feasible and frequently guided clinical decisions, mainly supporting treatment de-escalation. MRD was highly specific but less sensitive. Prospective studies are needed to define optimal testing intervals and validate MRD-guided strategies.
Authors
- Evgeni Gershman (ORCID: https://orcid.org/0000-0002-6994-4451)
- Roni Gillis (ORCID: https://orcid.org/0000-0001-6226-2573)
- Jaber Salim
- Yoav Manaster
- Elizabeth Dudnik (ORCID: https://orcid.org/0000-0001-6971-3576)
- Tamar Zahavi
- Noam Asna (ORCID: https://orcid.org/0009-0007-1720-069X)
- Adar Yaacov (ORCID: https://orcid.org/0000-0002-6106-2307)
- Osnat Moreh Rahav
- Reham Basheer
- Arnon Makori
- Michael Peer
- Nir Peled
- Basel Afifi
Institutions
- Ben-Gurion University of the Negev (IL)
- Tel Aviv University (IL)
- Hebrew University of Jerusalem (IL)
- Kaplan Medical Center (IL)
- Assuta Medical Center (IL)
- Shaare Zedek Medical Center (IL)
- Ligand Pharmaceuticals (United Kingdom) (GB)
- Weizmann Institute of Science (IL)
Publication Details
- Journal
- Cancers
- Published
- 2026-04-14
- DOI
- https://doi.org/10.3390/cancers18081246
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00